Literature DB >> 28070877

Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease.

Giovanni Maria Rossi1, Rossana Rocco1, Eugenia Accorsi Buttini1, Chiara Marvisi1, Augusto Vaglio2.   

Abstract

Retroperitoneal fibrosis (RPF) is a rare disease characterised by fibrous tissue proliferation in the retroperitoneum, with encasement of the ureters and large vessels of the abdomen as the most destructive of potentially severe complications. It can either be idiopathic, or secondary to infections, malignancies, or the use of certain drugs. The idiopathic form accounts for approximately 75% of the cases, and is usually responsive to immunosuppressive therapy. In recent years, the emergence of a new clinical entity, IgG4-related disease (IgG4-RD), shed light on many fibro-inflammatory disorders once thought to be separate clinical entities, although frequently associated in the so-called multifocal fibrosclerosis. Among these, together with sclerosing pancreatitis and cholangitis, pseudotumour of the orbit, idiopathic mediastinal fibrosis and other conditions, is idiopathic retroperitoneal fibrosis (IRF). Both IRF and IgG4-RD can be associated with a wide variety of disorders, usually governed by immune-mediated (and particularly auto-immune) mechanisms. In our review, we discuss the clinical and therapeutic challenges IRF presents to the internist, as well as the meaning of its recent inclusion in the IgG4-RD spectrum from a clinical practice standpoint.

Entities:  

Keywords:  ANCA; Hashimoto; Hydronephrosis; IgG4; Periaortitis; Retroperitoneal fibrosis; Vasculitis

Mesh:

Substances:

Year:  2017        PMID: 28070877     DOI: 10.1007/s11739-016-1599-z

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  80 in total

1.  Drug-induced retroperitoneal fibrosis: short aetiopathogenetic note, from the past times of ergot-derivatives large use to currently applied bio-pharmacology.

Authors:  C Alberti
Journal:  G Chir       Date:  2015 Jul-Aug

2.  Peri-renal collateral circles.

Authors:  Alessandra Palmisano; Rocco Cobelli; Carlo Buzio; Augusto Vaglio
Journal:  Urology       Date:  2009-05-24       Impact factor: 2.649

3.  Tocilizumab in refractory aortitis: study on 16 patients and literature review.

Authors:  Javier Loricera; Ricardo Blanco; Santos Castañeda; Alicia Humbría; Norberto Ortego-Centeno; Javier Narváez; Cristina Mata; Sheila Melchor; Elena Aurrecoechea; Jaime Calvo-Alén; Pau Lluch; Concepción Moll; Mauricio Mínguez; Gabriel Herrero-Beaumont; Beatriz Bravo; Esteban Rubio; Mercedes Freire; Enriqueta Peiró; Carmen González-Vela; Javier Rueda-Gotor; Trinitario Pina; Natalia Palmou-Fontana; Vanesa Calvo-Río; Francisco Ortiz-Sanjuán; Miguel Ángel González-Gay
Journal:  Clin Exp Rheumatol       Date:  2014-05-15       Impact factor: 4.473

4.  Treatment of retroperitoneal fibrosis by mycophenolate mofetil and corticosteroids.

Authors:  W Grotz; I von Zedtwitz; M Andre; P Schollmeyer
Journal:  Lancet       Date:  1998-10-10       Impact factor: 79.321

5.  Corrigendum to: 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases.

Authors:  R Erbel; V Aboyans; C Boileau; E Bossone; R Di Bartolomeo; H Eggebrecht; A Evangelista; V Falk; H Frank; O Gaemperli; M Grabenwoger; A Haverich; B Iung; A John Manolis; F Meijboom; C A Nienaber; Marco Roffi; H Rousseau; U Sechtem; Per A Sirnes; R S von Allmen; C J M Vrints
Journal:  Eur Heart J       Date:  2015-06-29       Impact factor: 29.983

6.  2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC).

Authors:  Raimund Erbel; Victor Aboyans; Catherine Boileau; Eduardo Bossone; Roberto Di Bartolomeo; Holger Eggebrecht; Arturo Evangelista; Volkmar Falk; Herbert Frank; Oliver Gaemperli; Martin Grabenwöger; Axel Haverich; Bernard Iung; Athanasios John Manolis; Folkert Meijboom; Christoph A Nienaber; Marco Roffi; Hervé Rousseau; Udo Sechtem; Per Anton Sirnes; Regula S von Allmen; Christiaan J M Vrints
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

7.  (18)F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease.

Authors:  Verena Ruhlmann; Thorsten Dirk Poeppel; Alexander Sascha Brandt; Johannes Grüneisen; Marcus Ruhlmann; Jens Matthias Theysohn; Michael Forsting; Andreas Bockisch; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-11       Impact factor: 9.236

8.  Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4.

Authors:  Yoh Zen; Manabu Onodera; Dai Inoue; Azusa Kitao; Osamu Matsui; Takahiro Nohara; Mikio Namiki; Satomi Kasashima; Atsuhiro Kawashima; Yasushi Matsumoto; Kazuyoshi Katayanagi; Tetsuya Murata; Shin Ishizawa; Noriko Hosaka; Ken Kuriki; Yasuni Nakanuma
Journal:  Am J Surg Pathol       Date:  2009-12       Impact factor: 6.394

9.  Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis?

Authors:  Marina N Magrey; M Elaine Husni; Irving Kushner; Leonard H Calabrese
Journal:  Arthritis Rheum       Date:  2009-05-15

10.  Idiopathic retroperitoneal fibrosis: a role for mycophenolate mofetil.

Authors:  R D Swartz; A M Lake; W W Roberts; G J Faerber; J S Wolf
Journal:  Clin Nephrol       Date:  2008-04       Impact factor: 0.975

View more
  15 in total

Review 1.  Erdheim-Chester disease: a rapidly evolving disease model.

Authors:  Francesco Pegoraro; Matthias Papo; Valerio Maniscalco; Frédéric Charlotte; Julien Haroche; Augusto Vaglio
Journal:  Leukemia       Date:  2020-06-26       Impact factor: 11.528

Review 2.  IgG4-related disease: a complex under-diagnosed clinical entity.

Authors:  Sujani Yadlapati; Elijah Verheyen; Petros Efthimiou
Journal:  Rheumatol Int       Date:  2017-07-05       Impact factor: 2.631

3.  [Clinical features of hydronephrosis induced by retroperitoneal fibrosis: 17 cases reports].

Authors:  S B Liu; H Gao; Y C Feng; J Li; T Zhang; L Wan; Y Y Liu; S G Li; C H Luo; X W Zhang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-18

Review 4.  [New (and old) aspects of retroperitoneal fibrosis].

Authors:  A S Brandt; N M Dreger; E Müller; S Kukuk; S Roth
Journal:  Urologe A       Date:  2017-07       Impact factor: 0.639

5.  Serum IgG4 Concentration Is a Potential Predictive Biomarker in Glucocorticoid Treatment for Idiopathic Retroperitoneal Fibrosis.

Authors:  Shoichiro Mukai; Naotaka Sakamoto; Hiroaki Kakinoki; Tadamasa Shibuya; Ryosuke Moriya; Kiyoaki Nishihara; Mitsuru Noguchi; Toshitaka Shin; Naohiro Fujimoto; Tsukasa Igawa; Tatsu Ishii; Nobuhiro Haga; Hideki Enokida; Masatoshi Eto; Tomomi Kamba; Hideki Sakai; Seiichi Saito; Naoki Terada; Toshiyuki Kamoto
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

6.  Concurrent presentation of IgG4-related tubulointerstitial nephritis and ANCA MPO crescentic glomerulonephritis.

Authors:  Henry H L Wu; Claire C Y Wang; Alexander Woywodt; Arvind Ponnusamy
Journal:  Clin Nephrol Case Stud       Date:  2022-07-04

7.  Use of rituximab in idiopathic retroperitoneal fibrosis.

Authors:  Veronika Boyeva; Hatim Alabsi; Michael A Seidman; Ryan Paterson; Jason Kur; Luke Y C Chen; Silvia D Chang; Mollie Carruthers
Journal:  BMC Rheumatol       Date:  2020-08-06

8.  Clinical and Prognostic Significance of Serum IgG4 in Chronic Periaortitis. An Analysis of 113 Patients.

Authors:  Federica Maritati; Rossana Rocco; Eugenia Accorsi Buttini; Chiara Marvisi; Maria Nicastro; Maria L Urban; Paride Fenaroli; Francesco Peyronel; Giuseppe D Benigno; Alessandro A Palumbo; Domenico Corradi; Giacomo Emmi; Nicolò Pipitone; Alessandra Palmisano; Augusto Vaglio
Journal:  Front Immunol       Date:  2019-04-04       Impact factor: 7.561

9.  IgG4-related aortitis/periaortitis and periarteritis: a distinct spectrum of IgG4-related disease.

Authors:  Linyi Peng; Panpan Zhang; Jieqiong Li; Zheng Liu; Hui Lu; Liang Zhu; Xiaorong Wang; Fei Teng; Xuemei Li; Huifang Guo; Yunyun Fei; Wen Zhang; Yan Zhao; Xiaofeng Zeng; Fengchun Zhang
Journal:  Arthritis Res Ther       Date:  2020-05-04       Impact factor: 5.156

10.  Improved clinical outcomes of tocilizumab versus cyclophosphamide for IgG4-related disease: insights from a prospective IgG4-related disease registry.

Authors:  Ji Zongfei; Zhang Lijuan; Sun Ying; Liu Dongmei; Wu Sifan; Kong Xiufang; Ma Lingying; Liu Yun; Ma Lili; Chen Huiyong; Jiang Lindi
Journal:  Ther Adv Chronic Dis       Date:  2021-06-30       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.